PORTFOLIO

Our activities as a dedicated private equity healthcare investor date back to the late 1980s. At that time, providing start-up and growth capital to innovative healthcare companies was not commonplace. In fact, we were one of the first to assume this role. As a result, we have grown to become one of the most experienced healthcare investors in Europe. Over time, we have raised a suite of closed-end investment vehicles that target private companies only, the latest two being LSP 6 and LSP HEF 2. Combined, we have raised through all our private equity funds more than €1.6 billion, making it the largest franchise within our firm.
 

HotSpot Therapeutics, Inc. is a biotechnology company pioneering the discovery and development of small molecule allosteric therapies targeting regulatory sites on proteins referred to as “natural hotspots visit website

T-knife is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts). visit website

Re-Inventing treatment of herpes infections.

Eyedrops for presbyopia visit website

Micro-organoid technology for precision cancer therapy and improved drug discovery visit website

Evommune is developing and discovering unique therapies that help patients with chronic inflammatory diseases
.
visit website

Egle Therapeutics is developing a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Treg starving. visit website

Transformative therapeutics to preserve brain function and enhance resilience to neurodegenerative diseases. visit website

AviadoBio is developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). visit website

Perfuze is an Irish medical device company developing and commercializing new products for the treatment of ischemic stroke. visit website

Nobi is commercializing a silver tech platform enabling elderly people to live healthier at home, whereever that might be. visit website

New Amsterdam Pharma is developing lipid-lowering therapies for diseases with large unmet need. visit website

Neurent Medical is dedicated to developing highly innovative non-surgical interventions that treat chronic inflammatory Sino-Nasal diseases. visit website

OneProjects are developing VERAFEYE, a connected platform technology to revolutionise the treatment of AFib and cardiac arrhythmias. visit website

Dutch biotech company developing an innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants. visit website

Dutch clinical stage biopharmaceutical company developing a treatment for acute kidney injury. visit website

FoRx Therapeutics focuses on drugging key molecular targets involved in the DNA Replication Stress as a new approach in the developments. visit website

Bringing knowledge, experience and science together to discover, develop and deliver therapies for CNS disorders. visit website

Belgian medical technology company focused on the development of novel ophthalmic implants for glaucoma visit website

US biotech company developing engineered natural killer (NK) cell therapies visit website

Amolyt Pharma is a company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases
visit website

Imcyse develops active specific immunotherapies for the treatment and prevention of severe chronic diseases visit website

Young Paris based company pioneering enzymatic DNA synthesis visit website

Danish biotech startup using CRISPR-Cas to selectively eliminate specific bacterial strains visit website

Dutch biotech company commercializing an epilepsy drug with unprecedented efficacy for refractory patients with partial onset seizures.
visit website

Irish medical technology company commercializing garment-based pelvic floor muscle strengthening devices treating the cause of bladder leaks visit website

Digital health care company, leading in care pathway management visit website

US biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease visit website

Patient management platform for early detection of worsening heart failure visit website

Next generation DNA Damage Response (DDR) target pipeline with the potential to transform cancer therapy visit website

Novel therapeutic modality to induce functional knockdown of a target protein visit website

Medical device company focused on spine products visit website

Bioabsorbable vessel closure devices to enable minimally invasive heart procedures visit website

Next generation immuno-modulators acting on adaptive and innate immunity visit website

Therapies for heart failure and related Cardiovascular Diseases visit website

Developing treatments for patients with hyperoxaluria visit website

Developing Protein Therapeutics for High Unmet Medical needs visit website

Next-generation neo-epitope vaccines and oncolytic viruses visit website

Reversed Merger 2019

Therapies for autoimmune and immunology related diseases
visit website

Development of drugs for orphan diseases visit website

IPO 2019

Treatment of improper fluid balances in the body
visit website

Reversed Merger 2017

Developing Therapeutics to treat genetic diseases
visit website

IPO 2017

Therapies for lysosomal storage - and protein misfolding diseases
visit website

Acquired by Codman Neuro 2017

Innovative devices for minimally invasive stroke therapy

Acquired by Smith & Nephew 2017

First treatment healing rotator cuff disease
visit website

User-friendly, appealing and highly accurate insulin patch pump therapy for diabetes patients. visit website

mRNA immunotherapies for oncology and infectious diseases visit website

ONWARD is creating technologies to improve the movement, independence, and health of people with spinal cord injury. visit website

Spontaneous growth of natural heart valves and vessels visit website

Ultra-rapid diagnosis of infections visit website

IPO 2017

Innovative immunology treatments to improve the lives of people suffering from severe autoimmune diseases and cancer.

Acquired by Bruker 2017

Light sheet microscopy
visit website

IPO 2016

Innovative full-length bispecific and trispecific antibody therapeutics for oncology.
visit website

IPO 2016

Ultra-rapid diagnosis of infections

IPO 2016

Orthobiological products for tissue and fracture repair
visit website

Minimally invasive treatment of bone fractures visit website

Minimally invasive reshaping of heart valve visit website

Prevention of drug misadministration at the bedside visit website

Treatment of severe hospitalized Influenza visit website

Next-generation glucose measuring devices visit website

Acquired by BioMarin 2015

Development of drugs for Duchenne Muscular Dystrophy

Acquired by Agilent Technologies 2015

Commercialization of medical instruments and laboratory products
visit website

Acquired by Intrexon (now Precigen) 2015

Oral delivery of complex biological medicines
visit website

IPO 2015

Novell cell therapies
visit website

Acquired by Medtronic 2014

Medical device for treatment of Parkinson's disease

Acquired by Vectura 2014

Novel medical solutions for lung disease
visit website

IPO 2014

Development of drugs for Alzheimer's disease

IPO 2014

Innovative treatments for heart disease

IPO 2014

Innovative cancer treatments

Acquired by Agenus 2014

Innovative cancer treatments

Acquired by GSK 2013

Breakthrough vaccines for infectious diseases

Acquired by Salix 2013

Novel treatments for specialist care

Acquired by Ipsen 2013

Novel treatment options for pain and inflammation

Acquired by Dr Reddy 2013

Preparation and development of injectable drugs

Acquired by Syngenta 2013

Next-generation crop protection

Acquired by Post foods 2013

Commercialization of probiotic foodbars

Acquired by LDC

Novel drugs for psychiatric disorders
visit website

Acquired by Syngenta 2012

Advanced crop protection technologies

Acquired by Tigenix 2011

Innovative treatments for bowel disorders and other diseases

Acquired by Edwards 2010

Commercialization of cardiovascular monitoring devices

Acquired by C.R. Bard 2010

State-of-the-art medical devices for heart disease

Acquired by Shire 2010

Innovative treatments for bowel disease

IPO 2010

Novel treatment options for diabetes and other diseases
visit website

IPO 2010

Development of drugs for rare and serious diseases

Acquired by Cosmo 2009

Novel drugs for bladder disorders and inflammatory diseases

Acquired by Daiichi Sankyo 2008

Innovative cancer treatments

IPO 2007

Advanced platform technologies to enable the development of drugs
visit website

Acquired by Shire 2006

Development of drug for rare and fatal disease

Acquired by Pharming 2006

Products for medical problems associated with aging

Acquired by Astra Zeneca 2006

Innovative cancer treatments

IPO 2000

Development of vaccines

IPO 1999

Commercialization of vaccines for infectious disease

IPO 2000

Precise identification of diseases and disorders in humans

IPO 1996

Diagnostics and laboratory testing equipment

Acquired by Leica

Labeling and detection of biological molecules
visit website

Introgene

Merged with U-Bisys into Crucell

Development of vaccines

Ness

Acquired by Bioness

Innovative rehabilitation products

Quadrant

IPO

Drug formulation

Biora

Acquired by Straumann

Commercialization of products used by dentists and oral surgeons

U-Bisys

Merged with Introgene into Crucell

Innovative drug development platform



Follow us

PORTFOLIO

Our activities as a dedicated private equity healthcare investor date back to the late 1980s. At that time, providing start-up and growth capital to innovative healthcare companies was not commonplace. In fact, we were one of the first to assume this role. As a result, we have grown to become one of the most experienced healthcare investors in Europe. Over time, we have raised a suite of closed-end investment vehicles that target private companies only, the latest two being LSP 6 and LSP HEF 2. Combined, we have raised through all our private equity funds more than €1.6 billion, making it the largest franchise within our firm.
 

HotSpot Therapeutics, Inc. is a biotechnology company pioneering the discovery and development of small molecule allosteric therapies targeting regulatory sites on proteins referred to as “natural hotspots visit website

T-knife is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts). visit website

Re-Inventing treatment of herpes infections.

Eyedrops for presbyopia visit website

Micro-organoid technology for precision cancer therapy and improved drug discovery visit website

Evommune is developing and discovering unique therapies that help patients with chronic inflammatory diseases
.
visit website

Egle Therapeutics is developing a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Treg starving. visit website

Transformative therapeutics to preserve brain function and enhance resilience to neurodegenerative diseases. visit website

AviadoBio is developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). visit website

Perfuze is an Irish medical device company developing and commercializing new products for the treatment of ischemic stroke. visit website

Nobi is commercializing a silver tech platform enabling elderly people to live healthier at home, whereever that might be. visit website

New Amsterdam Pharma is developing lipid-lowering therapies for diseases with large unmet need. visit website

Neurent Medical is dedicated to developing highly innovative non-surgical interventions that treat chronic inflammatory Sino-Nasal diseases. visit website

OneProjects are developing VERAFEYE, a connected platform technology to revolutionise the treatment of AFib and cardiac arrhythmias. visit website

Dutch biotech company developing an innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants. visit website

Dutch clinical stage biopharmaceutical company developing a treatment for acute kidney injury. visit website

FoRx Therapeutics focuses on drugging key molecular targets involved in the DNA Replication Stress as a new approach in the developments. visit website

Bringing knowledge, experience and science together to discover, develop and deliver therapies for CNS disorders. visit website

Belgian medical technology company focused on the development of novel ophthalmic implants for glaucoma visit website

US biotech company developing engineered natural killer (NK) cell therapies visit website

Amolyt Pharma is a company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases
visit website

Imcyse develops active specific immunotherapies for the treatment and prevention of severe chronic diseases visit website

Young Paris based company pioneering enzymatic DNA synthesis visit website

Danish biotech startup using CRISPR-Cas to selectively eliminate specific bacterial strains visit website

Dutch biotech company commercializing an epilepsy drug with unprecedented efficacy for refractory patients with partial onset seizures.
visit website

Irish medical technology company commercializing garment-based pelvic floor muscle strengthening devices treating the cause of bladder leaks visit website

Digital health care company, leading in care pathway management visit website

US biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease visit website

Patient management platform for early detection of worsening heart failure visit website

Next generation DNA Damage Response (DDR) target pipeline with the potential to transform cancer therapy visit website

Novel therapeutic modality to induce functional knockdown of a target protein visit website

Medical device company focused on spine products visit website

Bioabsorbable vessel closure devices to enable minimally invasive heart procedures visit website

Next generation immuno-modulators acting on adaptive and innate immunity visit website

Therapies for heart failure and related Cardiovascular Diseases visit website

Developing treatments for patients with hyperoxaluria visit website

Developing Protein Therapeutics for High Unmet Medical needs visit website

Next-generation neo-epitope vaccines and oncolytic viruses visit website

Reversed Merger 2019

Therapies for autoimmune and immunology related diseases
visit website

Development of drugs for orphan diseases visit website

IPO 2019

Treatment of improper fluid balances in the body
visit website

Reversed Merger 2017

Developing Therapeutics to treat genetic diseases
visit website

IPO 2017

Therapies for lysosomal storage - and protein misfolding diseases
visit website

Acquired by Codman Neuro 2017

Innovative devices for minimally invasive stroke therapy

Acquired by Smith & Nephew 2017

First treatment healing rotator cuff disease
visit website

User-friendly, appealing and highly accurate insulin patch pump therapy for diabetes patients. visit website

mRNA immunotherapies for oncology and infectious diseases visit website

ONWARD is creating technologies to improve the movement, independence, and health of people with spinal cord injury. visit website

Spontaneous growth of natural heart valves and vessels visit website

Ultra-rapid diagnosis of infections visit website

IPO 2017

Innovative immunology treatments to improve the lives of people suffering from severe autoimmune diseases and cancer.

Acquired by Bruker 2017

Light sheet microscopy
visit website

IPO 2016

Innovative full-length bispecific and trispecific antibody therapeutics for oncology.
visit website

IPO 2016

Ultra-rapid diagnosis of infections

IPO 2016

Orthobiological products for tissue and fracture repair
visit website

Minimally invasive treatment of bone fractures visit website

Minimally invasive reshaping of heart valve visit website

Prevention of drug misadministration at the bedside visit website

Treatment of severe hospitalized Influenza visit website

Next-generation glucose measuring devices visit website

Acquired by BioMarin 2015

Development of drugs for Duchenne Muscular Dystrophy

Acquired by Agilent Technologies 2015

Commercialization of medical instruments and laboratory products
visit website

Acquired by Intrexon (now Precigen) 2015

Oral delivery of complex biological medicines
visit website

IPO 2015

Novell cell therapies
visit website

Acquired by Medtronic 2014

Medical device for treatment of Parkinson's disease

Acquired by Vectura 2014

Novel medical solutions for lung disease
visit website

IPO 2014

Development of drugs for Alzheimer's disease

IPO 2014

Innovative treatments for heart disease

IPO 2014

Innovative cancer treatments

Acquired by Agenus 2014

Innovative cancer treatments

Acquired by GSK 2013

Breakthrough vaccines for infectious diseases

Acquired by Salix 2013

Novel treatments for specialist care

Acquired by Ipsen 2013

Novel treatment options for pain and inflammation

Acquired by Dr Reddy 2013

Preparation and development of injectable drugs

Acquired by Syngenta 2013

Next-generation crop protection

Acquired by Post foods 2013

Commercialization of probiotic foodbars

Acquired by LDC

Novel drugs for psychiatric disorders
visit website

Acquired by Syngenta 2012

Advanced crop protection technologies

Acquired by Tigenix 2011

Innovative treatments for bowel disorders and other diseases

Acquired by Edwards 2010

Commercialization of cardiovascular monitoring devices

Acquired by C.R. Bard 2010

State-of-the-art medical devices for heart disease

Acquired by Shire 2010

Innovative treatments for bowel disease

IPO 2010

Novel treatment options for diabetes and other diseases
visit website

IPO 2010

Development of drugs for rare and serious diseases

Acquired by Cosmo 2009

Novel drugs for bladder disorders and inflammatory diseases

Acquired by Daiichi Sankyo 2008

Innovative cancer treatments

IPO 2007

Advanced platform technologies to enable the development of drugs
visit website

Acquired by Shire 2006

Development of drug for rare and fatal disease

Acquired by Pharming 2006

Products for medical problems associated with aging

Acquired by Astra Zeneca 2006

Innovative cancer treatments

IPO 2000

Development of vaccines

IPO 1999

Commercialization of vaccines for infectious disease

IPO 2000

Precise identification of diseases and disorders in humans

IPO 1996

Diagnostics and laboratory testing equipment

Acquired by Leica

Labeling and detection of biological molecules
visit website

Introgene

Merged with U-Bisys into Crucell

Development of vaccines

Ness

Acquired by Bioness

Innovative rehabilitation products

Quadrant

IPO

Drug formulation

Biora

Acquired by Straumann

Commercialization of products used by dentists and oral surgeons

U-Bisys

Merged with Introgene into Crucell

Innovative drug development platform